DRD2 and schizophrenia: Olanzapine's exact mechanism of action as a therapeutic agent in schizophrenia is relatively unknown, but it is considered to act as an antagonist to dopamine D2 receptors along with rapid ligand-receptor dissociation kinetics which helps to decrease extrapyramidal symptoms [16].